Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: Current surfactant therapy requires endotracheal intubation and application of positive pressure ventilation. Instillation of the drug itself can be complicated by 'peridosing adverse events' including, but not limited to, desaturations, bradycardias, changes in blood pressure, drug reflux and even the need for reintubations. Increasing use of noninvasive ventilatory support for neonatal respiratory distress syndrome has motivated clinicians and researchers to look for alternate ways of introducing surfactants to patients. Aerosolized surfactants have been tested in animal models of respiratory distress syndrome. In addition, four small clinical studies have been performed to date. The effectiveness of this form of treatment requires further study, however, which will need to include optimizing the dose of aerosolized surfactant, choosing particle size, developing the best delivery system, and using a surfactant formulation that maintains its activity once aerosolized. SUMMARY:
|
Authors | Jan Mazela, T Allen Merritt, Neil N Finer |
Journal | Current opinion in pediatrics
(Curr Opin Pediatr)
Vol. 19
Issue 2
Pg. 155-62
(Apr 2007)
ISSN: 1040-8703 [Print] United States |
PMID | 17496758
(Publication Type: Journal Article, Review)
|
Chemical References |
- Aerosols
- Pulmonary Surfactants
|
Topics |
- Administration, Inhalation
- Aerosols
- Animals
- Continuous Positive Airway Pressure
- Humans
- Infant, Newborn
- Pulmonary Surfactants
(administration & dosage)
- Respiratory Distress Syndrome, Newborn
(drug therapy, physiopathology)
|